TOP STORY Gamma Interferon Prompts Stem Cell Response to Fight Infection Invading bacteria can be a call-to-arms, awaking the sleeping stem cells and prompting them to produce immune system cells that fight the foreign organisms. The “bugler” that awakes the stem cells in this battle is gamma interferon. [Press release from Baylor College of Medicine discussing online prepublication in Nature]
|
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) LABORATORY RESEARCH Quiescent Hematopoietic Stem Cells are Activated by IFN-Gamma in Response to Chronic Infection Here researchers show, using an in vivo mouse model of Mycobacterium avium infection, that an increased proportion of long-term repopulating hematopoietic stem cells proliferate during M. avium infection, and that this response requires interferon (IFN)-gamma but not interferon-alpha signalling. [Nature] Pro Isomerization in MLL1 PHD3-Bromo Cassette Connects H3K4me Readout to CyP33 and HDAC-Mediated Repression The MLL1 gene is a frequent target for recurrent chromosomal translocations, resulting in transformation of hematopoietic precursors into leukemia stem cells. Here, researchers report on structure-function studies that elucidate molecular events in MLL1 binding of histone H3K4me3/2 marks and recruitment of the cyclophilin CyP33. [Cell] PD-L1 has Distinct Functions in Hematopoietic and Nonhematopoietic Cells in Regulating T Cell Responses During Chronic Infection in Mice Here researchers used bone marrow chimeric mice to examine the effects of PD-L1 deficiency in hematopoietic or nonhematopoietic cells during lymphocytic choriomeningitis virus clone 13 (LCMV CL-13) infection. [J Clin Invest] The Endocytic Adaptor Numb Regulates Thymus Size by Modulating Pre-TCR Signaling During Asymmetric Division Researchers found that Numb determines the levels of pre-TCR signaling in dividing thymocytes and, ultimately, the size of the pool from which mature T lymphocytes are selected. [Blood] A Monoclonal Antibody Against Mutated Nucleophosmin1 for the Molecular Diagnosis of Acute Myeloid Leukemias Mutations in the nucleophosmin 1 (NPM1) gene are the most frequent genetic aberrations of acute myeloid leukemia (AML), and define a clinically distinct subset of AML. A monoclonal antibody (T26) was raised against a 19-aminoacid polypeptide containing the unique C-terminus of the type A NPM1 mutant protein. [Blood] Telomere Dysfunction and Fusion During the Progression of Chronic Lymphocytic Leukemia: Evidence for a Telomere Crisis Researchers performed single-molecule telomere length and telomere fusion analysis in patients at different stages of chronic lymphocytic leukemia. [Blood] BAALC-Associated Gene Expression Profiles Define IGFBP7 as a Novel Molecular Marker in Acute Leukemia To identify BAALC-associated genes that give insights into its functional role in chemotherapy resistance, gene expression signatures differentiating high from low BAALC expressers were generated from normal CD34+ progenitors, T-acute lymphoblastic leukemia and acute myeloid leukemia samples. [Leukemia] Effective Targeting of STAT5-Mediated Survival in Myeloproliferative Neoplasms Using ABT-737 Combined with Rapamycin Here, researchers have retrovirally transduced wild-type or Gab2(-/-) mouse bone marrow cells expressing STAT5(aS711F) and transplanted into irradiated recipient mice to test an in vivo myeloproliferative disease model. [Leukemia] CLINICAL RESEARCH Acquired Mutations in the Genes Encoding IDH1 and IDH2 Both are Recurrent Aberrations in Acute Myeloid Leukemia: Prevalence and Prognostic Value Here, researchers demonstrate in 893 newly diagnosed cases of acute myeloid leukemia mutations in the IDH1 (6%) and IDH2 (11%) genes. [Blood] Preemptive Alloimmune Intervention in High-Risk Pediatric Acute Lymphoblastic Leukemia Patients Guided by Minimal Residual Disease Level Before Stem Cell Transplantation Researchers conclude that in children with high-risk acute lymphoblastic leukemia, immunotherapy-based regimens after stem cell transplantation are feasible and may need to be further intensified to achieve total eradication of residual leukemic cells. [Leukemia]
|
|
INDUSTRY NEWS ARIAD Presents Updated Clinical Data on Its Investigational Pan-BCR-ABL Inhibitor, AP24534, in Drug-Resistant Chronic Myeloid Leukemia ARIAD Pharmaceuticals, Inc. announced updated clinical data from an ongoing Phase I study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia. [ARIAD Pharmaceuticals, Inc. Press Release] Hana Biosciences Announces Financing of Up to $100 Million Hana Biosciences Inc., announced that it has entered into an Investment Agreement with Warburg Pincus and Deerfield Management for the sale of up to $100 million in preferred stock. [Hana Biosciences Inc. Press Release] Human Genome Sciences Announces Results of Randomized Phase II Trial of Mapatumumab in Multiple Myeloma Human Genome Sciences, Inc. announced the results of its randomized Phase II trial of mapatumumab (HGS-ETR1) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma. [Human Genome Sciences, Inc. Press Release] Updated Results from Phase II Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromet’s Blinatumomab in Patients with Acute Lymphoblastic Leukemia Micromet, Inc. announced the presentation of updated results from a Phase II trial of the Company’s lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease positive acute lymphoblastic leukemia. [Micromet, Inc. Press Release] BioSante Announces FDA Orphan Drug Designation for GVAX Chronic Myeloid Leukemia Cancer Vaccine BioSante Pharmaceuticals, Inc. announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA’s Office of Orphan Products Development. [BioSante Pharmaceuticals, Inc. Press Release]
|
|
POLICY NEWS FDA Takes Issue with Genetic Tests from 23andMe, Four Other Firms The Food and Drug Administration has put five genetic test makers on notice that they must get federal approval before marketing their products for use by consumers. [Food and Drug Administration, United States] NIH Chief Collins Faces Stem Cell Donation Dilemma The NIH Advisory Committee to the Director, which advises NIH chief Francis Collins on whether lines meet the Obama ethics guidelines, faced the decision on whether 53 more stem cell lines should be added to that total. [National Institutes of Health, United States] NIH Researchers Explore How Healthy, Young Adults View the Role Genetics Plays in Improving Health Most healthy young adults place greater emphasis on health habits than on genetic risk factors when considering what causes common diseases, a research team from the National Human Genome Research Institute and the Henry Ford Health System in Detroit has found. [National Institutes of Health, United States] NICE Appraisal of Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura Eltrombopag (Revolade, GlaxoSmithKline) is not recommended for treating chronic immune (idiopathic) thrombocytopenic purpura in splenectomised adults who do not respond to other treatments, or as second-line treatment for non-splenectomised adults when surgery is not advised. [National Institute for Health and Clinical Excellence] Enhancing Peer Review: Advance Notice on Post-Submission Application Materials for NIH Training and Related Applications (NOT-OD-10-104) [National Institutes of Health, United States] PFINDR: Phenotype Finder IN Data Resources: A Tool to Support Cross-Study Data Discovery Among NHLBI Genomic Studies (UH2/UH3) (RFA-HL-11-020) [National Institutes of Health, United States] Clinical Trials for Medicines Section Updated [Medicines and Healthcare Products Regulatory Agency, United Kingdom] Advertising and Supply of Therapeutic Goods to Complementary Healthcare Professionals: Schedule 1 to the Therapeutic Goods Regulations [Therapeutic Goods Administration, Australia] Increased Transparency of the Prescription Medicine Regulatory Process [Therapeutic Goods Administration, Australia]
|
|
EVENTS International Society for Stem Cell Research (ISSCR) 8th Annual Meeting June 16-19, 2010 San Francisco, United States XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI) June 26-July 1, 2010 Berlin, Germany Translational Cancer Medicine 2010 – USA July 11-14, 2010 San Francisco, United States United Kingdom National Stem Cell Network (UKNSCN) Annual Scientific Conference July 12-14, 2010 Nottingham, United Kingdom Select Biosciences 3rd Annual Stem Cells Europe Conference August 24-25, 2010 Edinburgh, Scotland Select Biosciences 2nd Annual World Biobanking Summit August 24-25, 2010 Edinburgh, Scotland Select Biosciences Inaugural Cellular Therapy Summit August 24-25, 2010 Edinburgh, Scotland The European Molecular Biology Organization (EMBO) Meeting 2010 September 4-7, 2010 Barcelona, Spain International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting September 11-14, 2010 Belgirate, Italy Stem Cells USA & Regenerative Medicine Congress 2010 September 13-15, 2010 Philadelphia, United States Society for Hematology and Stem Cells (ISEH) 2010 Meeting September 15-18, 2010 Melbourne, Australia Stem Cells and Regeneration October 3-9, 2010 Woods Hole, United States American Association of Blood Banks (AABB) Annual Meeting 2010 October 9-12, 2010 Baltimore, United States Fraunhofer Life Science Symposium Leipzig 2010 October 29-30, 2010 Leipzig, Germany 52nd American Society of Hematology (ASH) Annual Meeting and Exposition December 4-7, 2010 Orlando, United States Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies) Business Development Manager Europe – Cell Therapy Products (Pall Corporation) Sr. Product Support and Training Specialist (CardianBCT) Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News. Visit here to post your career opportunities.
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or Suggestions? Email info@connexoncreative.com with your feedback.
|
| |
|